OSE Pharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
OSE Pharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

OSE Pharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

PR Newswire

PARIS, September 4, 2014 /PRNewswire/ --

OSE Pharma SA announced today that Emile Loria, MD, Chairman, will present a corporate update at the Rodman & Renshaw 16th Annual Global Investment Conference.

The presentation will take place on Wednesday, September 10, 2014 at 11:15 am Eastern Time at the New York Palace Hotel in New York, NY.

The study protocol of its pivotal Phase 3 trial with advanced stage IIIb invasive or metastatic stage IV NSCLC patients who express the HLA-A2 receptor (45% of the NSCLC population) has been recently approved both by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). OSE Pharma will conduct this pivotal Phase 3 in 2015.

About OSE Pharma 

OSE Pharma is a European cancer immunotherapy company with a multi-epitopes technology named Memopi® that directs the body's immune system to generate a specific cytotoxic T response to prevent cancer cell growth.

OSE Pharma's lead product, Texopi®, combines 10 epitopes directed against five tumor associated antigens. Its most advanced application is about to enter a pivotal Phase 3 study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2. Texopi® has an orphan drug status in the USA and is considered as personalized medicine in Europe in responder patients.

The Memopi® technology is ready for Phase 2 development in other cancer applications (ovarian, colon, breast) and is a suitable candidate for immune combination therapy.

Memopi® targets five tumor associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Memopi® contains ten optimized epitopes, derived from these five tumor antigens, which generate strong specific T cytotoxic responses that lead to the body's immune system preventing the growth of tumor cells expressing these tumor antigens.  

Since 2012 OSE Pharma is managed by Emile Loria and Dominique Costantini, two experienced biotech entrepreneurs, and is established in Paris - Hospital Cochin France. In 2014, the company completed the acquisition of Memopi® technology assets, worldwide rights and related know-how. The decision to acquire the Memopi® technology was based on Dr Emile Loria's previous experience as CEO of Epimmune, responsible for initiating the clinical development of this novel cancer immunotherapy product.


This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for OSE Pharma shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Press Contacts  

Dominique Costantini, Directeur Général
Mob +33-6-13-20-77-49

Alexis Peyroles, DAF
Mob : +33-6-11-51-19-77

HB ComCorp
Florence Portejoie
+33-1-58-18-32-58 /+33-6-88-84-81-74

Anne Hardy
+33-1-58-18-32-51 / +33-6-13-56-23-96

Citigate Dewe Rogerson
Laurence Bault

Lucie Larguier




blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document

Click here